NSCLC (NON-SMALL CELL LUNG CANCER)
Clinical trials for NSCLC (NON-SMALL CELL LUNG CANCER) explained in plain language.
Never miss a new study
Get alerted when new NSCLC (NON-SMALL CELL LUNG CANCER) trials appear
Sign up with your email to follow new studies for NSCLC (NON-SMALL CELL LUNG CANCER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted drug shows promise for hard-to-treat lung cancer
Disease control OngoingThis study tests a new drug called PLB1004 in people with advanced or spreading non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors and how safe it is. About 139 adults who have already tried oth…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Avistone Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New cancer cocktail aims to rev up immune system against tumors
Disease control OngoingThis early-stage trial tests a new drug called DECOY20, which is designed to wake up the immune system to fight cancer. It is being tested alone or with another drug (tislelizumab) in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Indaptus Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
AI-Designed vaccine takes on lung cancer in new trial
Disease control ENROLLING_BY_INVITATIONThis early-phase trial tests a personalized vaccine called Microlyvaq™ for people with advanced non-small cell lung cancer. The vaccine is custom-made for each patient using AI and quantum modeling to target their unique tumor mutations. It is given alongside standard chemotherap…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: EARLY_PHASE1 • Sponsor: Biogenea Pharmaceuticals Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New platform aims to predict lung cancer treatment success
Knowledge-focused OngoingThis study collects extra tissue samples from 200 people with advanced non-small cell lung cancer during routine biopsies. The goal is to train and validate a new diagnostic platform called Cybrid, which aims to predict how well a patient's tumor will respond to immunotherapy. Th…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New test could predict immunotherapy success from live tumor samples
Knowledge-focused OngoingThis observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC